CliffBio
small molecule

TAUVID

FLORTAUCIPIR F-18

Loss of exclusivityMay 2032latest FDA-listed patent expiry
CompanyAvid Radiopharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameTAUVID
Active ingredientFLORTAUCIPIR F-18
Strength100ML (8.1-100mCi/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJuly 2022
Marketing statusRX

Listed patents

PatentExpiresType
8932557May 2032substance

More from Avid Radiopharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

TAUVID patent cliff — loss of exclusivity May 2032 | CliffBio